cold water extract Search Results


90
Maitake Products Inc cold water extracts of maitake t1
Cold Water Extracts Of Maitake T1, supplied by Maitake Products Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/cold+water+extracts+of+maitake+t1/pm36014338-133-24-23
Average 90 stars, based on 1 article reviews
cold water extracts of maitake t1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
FEBICO Inc cold water extract of spirulina
( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of <t>Spirulina</t> extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.
Cold Water Extract Of Spirulina, supplied by FEBICO Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/cold+water+extract+of+spirulina/pmc04828654-109-5-9
Average 90 stars, based on 1 article reviews
cold water extract of spirulina - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Fisher Scientific cold ethanol:water extracts (4 and particle size)
( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of <t>Spirulina</t> extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.
Cold Ethanol:Water Extracts (4 And Particle Size), supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/cold+ethanol+water+extracts++4+and+particle+size+/pm28905481-65-12-39
Average 90 stars, based on 1 article reviews
cold ethanol:water extracts (4 and particle size) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
FutureCeuticals Inc powdered cold-water extract of humic shale
( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of <t>Spirulina</t> extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.
Powdered Cold Water Extract Of Humic Shale, supplied by FutureCeuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/powdered+cold+water+extract+of+humic+shale/us09327005-148-5-35
Average 90 stars, based on 1 article reviews
powdered cold-water extract of humic shale - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Rooibos Ltd standardized cold water-soluble extracts
( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of <t>Spirulina</t> extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.
Standardized Cold Water Soluble Extracts, supplied by Rooibos Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/standardized+cold+water+soluble+extracts/pm38958559-30-3-9
Average 90 stars, based on 1 article reviews
standardized cold water-soluble extracts - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BlueLight analytics inc cold-water extraction technique
( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of <t>Spirulina</t> extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.
Cold Water Extraction Technique, supplied by BlueLight analytics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/cold+water+extraction+technique/pm31081395-134-7-0
Average 90 stars, based on 1 article reviews
cold-water extraction technique - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Maitake Products Inc cold water extract
( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of <t>Spirulina</t> extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.
Cold Water Extract, supplied by Maitake Products Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cold+water+extract/cold+extract+water/pmc12992099-84-4-2
Average 86 stars, based on 1 article reviews
cold water extract - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of Spirulina extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.

Journal: Scientific Reports

Article Title: Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

doi: 10.1038/srep24253

Figure Lengend Snippet: ( a ) The influenza virus strains A/WSN/33(H1N1), A/TW/3446/02(H3N2), and B/TW/70555/05, and ( b ) the oseltamivir-resistant strains A/TW/70058/09(H1N1) and A/TW/147/09(H1N1), propagated on MDCK cells, all exhibited dose-dependent reductions in virus plaque formation after treatment with 0.375, 0.75, 1.5, and 3.0 mg/ml of Spirulina extract. Data represent the mean ± SD for three independent experiments. Statistical significance was determined by two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001. ( c ) The TCID 50 assay showed that Spirulina extract reduced virus production of the influenza A/TW/04/2014 (H7N9) virus.

Article Snippet: The cold water extract of Spirulina was supplied by FEBICO (Far East Bio-Tec Co., Taipei, Taiwan).

Techniques: Virus, Two Tailed Test

Antiviral activity of  Spirulina  extract against influenza virus strains in vitro .

Journal: Scientific Reports

Article Title: Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

doi: 10.1038/srep24253

Figure Lengend Snippet: Antiviral activity of Spirulina extract against influenza virus strains in vitro .

Article Snippet: The cold water extract of Spirulina was supplied by FEBICO (Far East Bio-Tec Co., Taipei, Taiwan).

Techniques: Activity Assay, Virus, In Vitro

( a ) 14-day acute oral toxicity study was conducted in Sprague-Dawley rats given 0, 1,000, 3,000, or 5,000 mg/kg of Spirulina extract. Body weight changes were tracked for ( a ) male and ( b ) female rats during the study period, and no significant changes were observed. ( a ) 14-day subacute study, in which Sprague-Dawley rats were subjected to repeated dosing with 750, 1,500, or 3,000 mg/kg/day of Spirulina extract for 14 consecutive days, was also conducted. Body weight changes for ( c ) male and ( d ) female rats were measured on Day 1, Day 8, and Day 14. All data are presented as mean ± SD (N = 10).

Journal: Scientific Reports

Article Title: Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

doi: 10.1038/srep24253

Figure Lengend Snippet: ( a ) 14-day acute oral toxicity study was conducted in Sprague-Dawley rats given 0, 1,000, 3,000, or 5,000 mg/kg of Spirulina extract. Body weight changes were tracked for ( a ) male and ( b ) female rats during the study period, and no significant changes were observed. ( a ) 14-day subacute study, in which Sprague-Dawley rats were subjected to repeated dosing with 750, 1,500, or 3,000 mg/kg/day of Spirulina extract for 14 consecutive days, was also conducted. Body weight changes for ( c ) male and ( d ) female rats were measured on Day 1, Day 8, and Day 14. All data are presented as mean ± SD (N = 10).

Article Snippet: The cold water extract of Spirulina was supplied by FEBICO (Far East Bio-Tec Co., Taipei, Taiwan).

Techniques:

( a ) A time of addition assay was conducted, in which 2.5 mg/mL of Spirulina extract was added at the indicated timepoints to MDCK cells infected with the A/WSN/33(H1N1) influenza strain. E 0 medium was overlaid on cultures at 9 hours post-infection, and supernatants were harvested at 12 hours post-infection. ( b ) Virus yields were determined by the plaque assay, and reported as a percentage of untreated controls. Data represent the mean ± SD for two independent experiments. Statistical analysis was performed with two-tailed unpaired t-test, and the statistical significance was determined to be * P ≤ 0.05, ** P ≤ 0.01, or *** P ≤ 0.001 for each treated group versus the virus control.

Journal: Scientific Reports

Article Title: Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

doi: 10.1038/srep24253

Figure Lengend Snippet: ( a ) A time of addition assay was conducted, in which 2.5 mg/mL of Spirulina extract was added at the indicated timepoints to MDCK cells infected with the A/WSN/33(H1N1) influenza strain. E 0 medium was overlaid on cultures at 9 hours post-infection, and supernatants were harvested at 12 hours post-infection. ( b ) Virus yields were determined by the plaque assay, and reported as a percentage of untreated controls. Data represent the mean ± SD for two independent experiments. Statistical analysis was performed with two-tailed unpaired t-test, and the statistical significance was determined to be * P ≤ 0.05, ** P ≤ 0.01, or *** P ≤ 0.001 for each treated group versus the virus control.

Article Snippet: The cold water extract of Spirulina was supplied by FEBICO (Far East Bio-Tec Co., Taipei, Taiwan).

Techniques: Infection, Virus, Plaque Assay, Two Tailed Test, Control

( a ) 5 × 10 5 PFUs of the influenza A/WSN/33(H1N1) virus was incubated with 1.5, 3, 6, or 12 mg/mL of Spirulina extract at room temperature for 2 hours, after which cultures underwent a 10 4 -fold dilution to derive samples containing ~50 PFU and negligible amounts of Spirulina extract, which were then used in a plaque assay to assess viral viability. ( b ) Plaque assays showed that plaque formation percentages for Spirulina extract-treated viruses were significantly lower than untreated controls. Statistical analysis was performed with the two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; **P < 0.01; ***P < 0.001. ( c ) Monolayer MDCK cells in 6-well plates were either treated with 3 mg/mL of Spirulina extract for 2 hours, after which the culture medium was replaced with fresh medium containing no Spirulina extract (the −3 ~ −1 group), or treated with 3 mg/mL of Spirulina extract just prior to and during viral adsorption (the −1 ~ +1 group). 50 P.F.U. of the influenza A/WSN/33(H1N1) virus were added to cultures at Hour 0, and a plaque assay was conducted to assess viral viability after 48 hours of incubation. ( d ) Plaque assays showed that the plaque formation percentage of the −3 ~ −1 group was comparable to the untreated virus control, while plaque formation was significantly inhibited in the −1 ~ +1 group. Statistical analysis was performed with the two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001 ( e ) Varying concentrations of Spirulina extract were added to 96-well plates containing 1% of guinea pig RBCs and 4 HA units of influenza A/WSN/33(H1N1), A/TW/3446/02(H3N2), or B/TW/70555/05 viruses. In the virus control column at far right, no Spirulina extract was added. Results showed that concentrations of Spirulina extract above 0.78 mg/mL were capable of inhibiting influenza hemagglutination.

Journal: Scientific Reports

Article Title: Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

doi: 10.1038/srep24253

Figure Lengend Snippet: ( a ) 5 × 10 5 PFUs of the influenza A/WSN/33(H1N1) virus was incubated with 1.5, 3, 6, or 12 mg/mL of Spirulina extract at room temperature for 2 hours, after which cultures underwent a 10 4 -fold dilution to derive samples containing ~50 PFU and negligible amounts of Spirulina extract, which were then used in a plaque assay to assess viral viability. ( b ) Plaque assays showed that plaque formation percentages for Spirulina extract-treated viruses were significantly lower than untreated controls. Statistical analysis was performed with the two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; **P < 0.01; ***P < 0.001. ( c ) Monolayer MDCK cells in 6-well plates were either treated with 3 mg/mL of Spirulina extract for 2 hours, after which the culture medium was replaced with fresh medium containing no Spirulina extract (the −3 ~ −1 group), or treated with 3 mg/mL of Spirulina extract just prior to and during viral adsorption (the −1 ~ +1 group). 50 P.F.U. of the influenza A/WSN/33(H1N1) virus were added to cultures at Hour 0, and a plaque assay was conducted to assess viral viability after 48 hours of incubation. ( d ) Plaque assays showed that the plaque formation percentage of the −3 ~ −1 group was comparable to the untreated virus control, while plaque formation was significantly inhibited in the −1 ~ +1 group. Statistical analysis was performed with the two-tailed unpaired t-test, and used as the basis to label results as ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; or *** P ≤ 0.001 ( e ) Varying concentrations of Spirulina extract were added to 96-well plates containing 1% of guinea pig RBCs and 4 HA units of influenza A/WSN/33(H1N1), A/TW/3446/02(H3N2), or B/TW/70555/05 viruses. In the virus control column at far right, no Spirulina extract was added. Results showed that concentrations of Spirulina extract above 0.78 mg/mL were capable of inhibiting influenza hemagglutination.

Article Snippet: The cold water extract of Spirulina was supplied by FEBICO (Far East Bio-Tec Co., Taipei, Taiwan).

Techniques: Virus, Incubation, Plaque Assay, Two Tailed Test, Adsorption, Control

Six-week-old female BALB/c mice were inoculated with 2 × 10 4 PFUs of the influenza A/WSN/33(H1N1) virus, after receiving Spirulina extract 4 hours prior to infection by oral gavage. Spirulina extract was again administered at 6 hours post-infection and twice daily thereafter for 4 days, at respective daily doses of 10, 25, or 50 mg/kg. Survival rates were improved in mice treated with Spirulina extract, as compared to vehicle-treated controls that did not receive Spirulina extract. Statistical analyses of the survival curves were performed using the Log-rank (Mantel-Cox) test compared each Spirulina extract treated group to the vehicle-treated group (n = 5 mice per group). *P < 0.05, **P < 0.01.

Journal: Scientific Reports

Article Title: Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

doi: 10.1038/srep24253

Figure Lengend Snippet: Six-week-old female BALB/c mice were inoculated with 2 × 10 4 PFUs of the influenza A/WSN/33(H1N1) virus, after receiving Spirulina extract 4 hours prior to infection by oral gavage. Spirulina extract was again administered at 6 hours post-infection and twice daily thereafter for 4 days, at respective daily doses of 10, 25, or 50 mg/kg. Survival rates were improved in mice treated with Spirulina extract, as compared to vehicle-treated controls that did not receive Spirulina extract. Statistical analyses of the survival curves were performed using the Log-rank (Mantel-Cox) test compared each Spirulina extract treated group to the vehicle-treated group (n = 5 mice per group). *P < 0.05, **P < 0.01.

Article Snippet: The cold water extract of Spirulina was supplied by FEBICO (Far East Bio-Tec Co., Taipei, Taiwan).

Techniques: Virus, Infection